Array BioPharma, Pierre Fabre deal

Array granted Pierre Fabre exclusive, worldwide rights, excluding the U.S., Canada, Japan, Korea and Israel, to develop and commercialize binimetinib ( MEK162) and encorafenib ( LGX818). Array received $30 million up front and is eligible to receive up to $425 million in milestones, plus double-digit royalties. Array and Pierre Fabre will split development costs 60/40. Array retains rights to the candidates in the excluded territories.

Array expects top-line data by year end from the Phase III NEMO trial of binimetinib to treat neuroblastoma Ras viral (v-Ras) oncogene (NRAS)-mutant melanoma and data next half from the Phase III COLUMBUS trial of encorafenib plus binimetinib to treat BRAF-negative melanoma. The partners plan to run new clinical trials in colorectal cancer and melanoma. ...